Sareum Holdings plc
(“Sareum” or the “Company”)
Director Subscription, Admission and Total Voting Rights
Cambridge, UK, 6 November 2026 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that, further to its announcement of 26 October 2026 and following the announcement of its results for the year ended 30 June 2026 on 2 November 2026, certain Directors of the Company have subscribed for, in aggregate, 214,285 new ordinary shares of 1.25 pence each in the capital of the Company ("Ordinary Shares") on the same terms (including the subscription price of 14 pence and warrant entitlement) as the subscription announced on 26 October 2026 (the "Director Subscription Shares").
The Director Subscription Shares have been subscribed for directly with the Company as follows:
Director | Director Subscription Shares | Purchase Price | Consideration | Resultant holding | % of enlarged issued share capital | Number of Warrants issued ** |
Dr Stephen Parker, Executive Chairman* | 107,143 | 14 pence | £15,000.02 | 512,188 | 0.31% | 107,143 |
Dr John Reader, Chief Scientific Officer* | 71,428 | 14 pence | £9,999.92 | 1,369,898 | 0.84% | 71,428 |
Clive Birch, Non-Executive Director | 35,714 | 14 pence | £4,999.96 | 154,437 | 0.09% | 35,714 |
Total | 214,285 | £29,999.90 | 214,285 |
* Includes Ordinary Shares held by spouses or other connected persons.
** Each Subscription Share carries one warrant to subscribe for one new Ordinary Share at an exercise price of 20 pence, exercisable at any time during the period of three years from 29 October 2026. In the event that the Company issues new Ordinary Shares for cash at a price per share lower than the then prevailing exercise price, the exercise price will rebase to that price.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange plc for the Director Subscription Shares, which will rank pari passu with the existing Ordinary Shares, to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. (London time) on or around 9 November 2026. The issue of the Director Subscription Shares is conditional on Admission.
Immediately following Admission, the total number of Ordinary Shares in issue will be 163,819,032 and the total number of voting rights will therefore be 163,819,032. No Ordinary Shares are held in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For Further Information:
Sareum Holdings plc Stephen Parker, Executive Chairman | 01223 497700 |
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman Singer Capital Markets (Joint Corporate Broker) Russell Cook / Patrick Weaver | 020 7409 3494 020 7496 3000 |
Oberon Capital (Joint Corporate Broker) Mike Seabrook / Nick Lovering | 020 3179 5300 |
ICR Healthcare (Financial PR) Jessica Hodgson / Lisa Lam / Tom Daniel | 020 3709 5700 |
About Sareum
Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for certain haematological cancers and has recently initiated a preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such as multiple sclerosis and Parkinson's disease.
The Company holds the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.com
The notifications below are made in accordance with the requirements of the UK Market Abuse Regulation.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Stephen Parker | ||||
2. | Reason for the notification | |||||
a) | Position / status | Executive Chairman | ||||
b) | Initial notification / amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Sareum Holdings plc | ||||
b) | LEI | 213800PKERN2DY8FFM72 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification Code | Ordinary Shares of 1.25 pence each ISIN: GB00BMC3RJ87 | ||||
b) | Nature of the transaction(s) | Subscription for new Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||||
e) | Date of the transaction | 6 November 2026 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | John Reader | ||||
2. | Reason for the notification | |||||
a) | Position / status | Chief Scientific Officer | ||||
b) | Initial notification / amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Sareum Holdings plc | ||||
b) | LEI | 213800PKERN2DY8FFM72 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification Code | Ordinary Shares of 1.25 pence each ISIN: GB00BMC3RJ87 | ||||
b) | Nature of the transaction(s) | Subscription for new Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||||
e) | Date of the transaction | 6 November 2026 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Clive Birch | ||||
2. | Reason for the notification | |||||
a) | Position / status | Non-Executive Director | ||||
b) | Initial notification / amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Sareum Holdings plc | ||||
b) | LEI | 213800PKERN2DY8FFM72 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification Code | Ordinary Shares of 1.25 pence each ISIN: GB00BMC3RJ87 | ||||
b) | Nature of the transaction(s) | Subscription for new Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | ||||
e) | Date of the transaction | 6 November 2026 | ||||
f) | Place of the transaction | London Stock Exchange, AIM | ||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.